Ocugen: FDA Lifts Hold on Application for COVID-19 Vaccine Candidate

  Ocugen, Inc.,  (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that the U.S. Food and Drug Administration (FDA) has lifted its clinical hold on the Company’s Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, known as COVAXIN™ outside the United States.

COVAXIN™ is a whole-virion inactivated COVID-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades.

https://www.biospace.com/article/releases/ocugen-inc-announces-u-s-fda-lifts-clinical-hold-on-the-submission-of-its-investigational-new-drug-application-for-its-covid-19-vaccine-candidate-covaxin-bbv152-/